Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 13

recruiting
3 968
countries
28
conditions
2 103

209 trials match your criteria

Neovascular age-related macular degeneration

Not recruiting

Study on the Effectiveness of OPT-302 and Ranibizumab for Patients with Wet Age-related Macular Degeneration

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab

Transitional cell carcinoma

Not recruiting

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab

Endocrine ophthalmopathy

Not recruiting

Study of Efgartigimod PH20 SC for Adults with Thyroid Eye Disease

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa

Hypertriglyceridaemia

Not recruiting

Study on Plozasiran and ARO-APOC3 for Adults with Severe Hypertriglyceridemia

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues

Cold urticaria

Not recruiting

Study on the Effectiveness and Safety of Barzolvolimab for Patients with Chronic Inducible Urticaria

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab

Pemphigoid

Not recruiting

Study on Efgartigimod Alfa and Prednisone for Adults with Bullous Pemphigoid

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug
Countries:LatviaLatvia
  • Participants:0–17 years
  • Substances:DIMENHYDRINATE

Colitis ulcerative

Not recruiting

Study on Rifamycin SV for Patients with Mild to Moderate Left-Sided Ulcerative Colitis

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Rifamycin Sodium

Severe myoclonic epilepsy of infancy+1

Not recruiting

Study on Long-Term Safety of Soticlestat for Patients with Dravet or Lennox-Gastaut Syndromes

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:0–17 years · 18–64 years
  • Substances:Soticlestat

Urinary tract infection

Not recruiting

Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Cilastatin

Gastric cancer

Not recruiting

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab

Psoriatic arthropathy

Not recruiting

Study of Risankizumab vs. Placebo for Patients with Active Psoriatic Arthritis and Inadequate Response to DMARD Therapy

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.